Survodutide vs Melanotan II
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideSexual Health & Libido
Melanotan II- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
- Half-Life
- ~7 days
- 1–2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 0.25–0.5 mg
- Frequency
- Once weekly
- Once daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Promotes skin tanning and melanin production
- Reduces UV exposure needed to tan
- Enhances libido and sexual function
- May suppress appetite
- Faster, deeper tan development
- Longer-lasting tan maintenance
- Potential photoprotective effects
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Nausea (very common, especially in first days)
- Facial flushing
- Spontaneous erections in men
- Darkening or changes in existing moles (monitor closely)
- +3 more
- Stacks With
- —
- —